What is Savara Inc. (SVRA)?

Savara Inc. (SVRA) is a stock in the Healthcare sector, Biotechnology industry. View full analysis on Stocks360.

What is the current price of SVRA?

The current price of SVRA is $4.82. Prices are updated in real time on Stocks360.

What is SVRA's price-to-earnings (PE) ratio?

SVRA's trailing twelve-month PE ratio is -8.31, based on current price and earnings per share data available on Stocks360.

What is SVRA's market capitalization?

SVRA's market capitalization is $990,317,200.00, placing it in the small-cap tier.

Savara Inc. (SVRA)

Stock analysis · NASDAQ · Healthcare · Biotechnology

$4.82

Market Cap

$990.32M

PE (TTM)

-8.31

EPS (TTM)

N/A

Dividend Yield

0.00%

Beta

0.25

Day Range

$4.75 – $4.97

52-wk Range

$3.86 – $7.01

Avg Volume

N/A

Volume

1.41M

Savara Inc. (SVRA) is a publicly traded company in the Healthcare sector. Latest price: $4.82. Market cap $990.32M. Trailing PE -8.31. Sign in to Stocks360 for full DCF valuation, fundamentals, technicals, and AI-driven analysis.

Get full analysis → Short-Term Analysis →

You have viewed 4 SEO analysis pages

Unlock saved watchlists, personalized setups, and referral credits with a free Stocks360 account.

Continue with free signup

1-Year Price

2025-10-31 · $4.15 2026-10-30 · $4.82 (+16.14%)

Earnings

Most Recent

Aug 11, 2026

EPS $-0.16 vs est. $-0.14

Missed by $0.02

Next Earnings

Nov 11, 2026

EPS estimate $-0.16

Proprietary Signals

Signal snapshot temporarily unavailable.

About Savara Inc.

Savara Inc. is a biopharmaceutical firm in the clinical development phase, specializing in therapies for uncommon respiratory conditions. Their primary investigational drug, molgramostim, is an inhaled form of granulocyte-macrophage colony-stimulating factor (GM-CSF). This compound is currently undergoing Phase III trials to address autoimmune pulmonary alveolar proteinosis. The company's main operations are situated in Austin, Texas.

Valuation

Trailing twelve months. Multiples relative to current market price.
P/E (TTM)	-8.31×
P/S (TTM)	0.00×
P/B	8.51×
PEG	0.65×
P/FCF (TTM)	-8.95×
EV / EBITDA	-7.04×
EV / Sales	0.00×
Earnings Yield	-11.40%
Free Cash Flow Yield	-11.17%

Fundamentals

Trailing twelve months. Source: financial statements via market data.
Enterprise Value	$978.63M
Net Income (TTM)	-$112.88M
Free Cash Flow (TTM)	-$110.66M
Net Debt	-$11.69M
Working Capital	$160.72M
Gross Margin	0.00%
Operating Margin	0.00%
Net Margin	0.00%
Return on Equity	-90.28%
Return on Invested Capital	-82.30%

Peers

Theravance Biopharma Inc

$17.03 · $884.18M